...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Polymyxin Susceptibility in Pseudomonas aeruginosa Linked to the MexXY-OprM Multidrug Efflux System
【24h】

Polymyxin Susceptibility in Pseudomonas aeruginosa Linked to the MexXY-OprM Multidrug Efflux System

机译:铜绿假单胞菌中的多粘菌素敏感性与MexXY-OprM多药外排系统相关

获取原文
获取原文并翻译 | 示例
           

摘要

The ribosome-targeting antimicrobial, spectinomycin (SPC), strongly induced the mexXY genes of the MexXY-OprM multidrug efflux system in Pseudomonas aeruginosa and increased susceptibility to the polycationic antimicrobials polymyxin B and polymyxin E, concomitant with a decrease in expression of the polymyxin resistance-promoting lipopolysaccharide (LPS) modification loci, arnBCADTEF and PA4773-74. Consistent with the SPC-promoted reduction in arn and PA4773-74 expression being linked to mexXY, expression of these LPS modification loci was moderated in a mutant constitutively expressing mexXY and enhanced in a mutant lacking the efflux genes. Still, the SPC-mediated increase in polymyxin susceptibility was retained in mutants lacking arnB and/or PA4773-74, an indication that their reduced expression in SPC-treated cells does not explain the enhanced polymyxin susceptibility. That the polymyxin susceptibility of a mutant strain lacking mexXY was unaffected by SPC exposure, however, was an indication that the unknown polymyxin resistance 'mechanism' is also influenced by the MexXY status of the cell. In agreement with SPC and MexXY influencing polymyxin susceptibility as a result of changes in the LPS target of these agents, SPC treatment yielded a decline in common polysaccharide antigen (CPA) synthesis in wild-type P. aeruginosa but not in the Delta mexXY mutant. A mutant lacking CPA still showed the SPC-mediated decline in polymyxin MICs, however, indicating that the loss of CPA did not explain the SPC-mediated MexXY-dependent increase in polymyxin susceptibility. It is possible, therefore, that some additional change in LPS promoted by SPC-induced mexXY expression impacted CPA synthesis or its incorporation into LPS and that this was responsible for the observed changes in polymyxin susceptibility.
机译:靶向核糖体的抗菌素壮观霉素(SPC)强烈诱导铜绿假单胞菌MexXY-OprM多药外排系统的mexXY基因,并增加了对多阳离子抗微生物剂多粘菌素B和多粘菌素E的敏感性,同时多粘菌素抗性的表达降低促进脂多糖(LPS)修饰基因座,arnBCADTEF和PA4773-74。与SPC促进的arn减少和PA4773-74表达与mexXY相关联,这些LPS修饰基因座的表达在组成型表达mexXY的突变体中被缓和,而在缺少外排基因的突变体中则增强。尽管如此,在缺乏arnB和/或PA4773-74的突变体中,SPC介导的多粘菌素敏感性增加仍然存在,这表明它们在SPC处理的细胞中表达的降低不能解释多粘菌素敏感性的增强。然而,缺乏mexXY的突变菌株的多粘菌素敏感性不受SPC暴露的影响,这表明未知的多粘菌素抗性“机制”也受细胞MexXY状态的影响。由于这些药剂的LPS靶点发生变化,SPC和MexXY会影响多粘菌素敏感性,因此SPC处理导致野生型铜绿假单胞菌的普通多糖抗原(CPA)合成下降,但Delta mexXY突变体却没有。缺少CPA的突变体仍然显示SPC介导的多粘菌毒素MICs下降,但是,这表明CPA的丧失并不能解释SPC介导的MexXY依赖性多粘菌素敏感性的增加。因此,由SPC诱导的mexXY表达促进的LPS的一些其他变化可能会影响CPA合成或将其掺入LPS,这可能是观察到的多粘菌素敏感性变化的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号